Asociación entre el biomarcador tumoral antígeno carbohidrato 125 y la insuficiencia cardíaca

Abstract

In the world, approximately 20 million people have heart failure (HF). Therefore, a biomarker indicating a state of congestion, treatment, and mortality prognosis is essential. For this purpose, the carbohydrate antigen 125 (CA125) can be used in clinical practice because a decrease in CA125 values <35 U/ml reduces mortality from any other factor within a year. The tumor biomarker, carbohydrate antigen 125, was associated with heart failure (HF) as an independent prognostic factor for all-cause mortality at one year (Hazard Ratio [HR]: 3.05, p= 0.002) when the CA125 value was ≥47.6 U/ml. Additionally, it was established as a congestion marker in HF patients with a CA125 value >35 U/ml. It will allow for the assessment of the risk of decompensation in the future and provide timely treatment, starting with depletion therapy, the use of diuretics, and potentially indicating palliative care.